Medicine

COPD vs Asthma for NEET PG: Spirometry, Reversibility and the Treatment Ladder Side by Side

Reflex · 15 Nov 2026 · 13 min read

Last updated: 15 Nov 2026

Simplified pair of lungs with trachea, right lung overinflated, on a pale blue disc: COPD vs asthma NEET PG
On this page

COPD and asthma can both present with breathlessness, cough and wheeze, so the diagnosis rests on the pattern of airflow limitation. In COPD the limitation is persistent and often progressive. In asthma it varies over time and in intensity.

This post sets the two conditions side by side on spirometry, bronchodilator reversibility and the stepwise treatment ladder. The criteria follow peer-reviewed summaries of GOLD 2023 and GINA 2021/2022, plus the 2013 Indian Chest Society guideline for Indian context. Both bodies have since published 2026 editions (GOLD, GINA); the figures below come from the earlier summaries.

Key Takeaways
  • COPD is confirmed by a post-bronchodilator FEV1/FVC below 0.7 (GOLD). Asthma is confirmed by evidence of variable airflow limitation, not by one fixed ratio.
  • GINA counts an adult FEV1 rise of more than 12% and more than 200 mL after a bronchodilator as reversibility, but reversibility alone does not separate COPD from asthma.
  • Classic asthma inflammation is eosinophilic, while COPD inflammation is usually dominated by neutrophils, CD8+ T cells and macrophages.
  • In India, biomass smoke is a strong COPD risk factor, so a non-smoker can still have COPD.
  • COPD therapy follows GOLD groups A, B and E, with ICS added only by exacerbations and eosinophils. Asthma therapy follows GINA steps built around ICS.
  • Long-acting bronchodilators without ICS are first-line in COPD but not appropriate in asthma.

COPD vs Asthma at a Glance

The table gathers the core contrasts in one place. Each row is explained, with its source, in the sections that follow.

FeatureAsthmaCOPD
Core abnormalityVariable expiratory airflow limitationPersistent, often progressive airflow obstruction
Diagnostic spirometryEvidence of variability: reversibility, PEF variability, provocation test, FEV1 variation between visits, FEV1 rise after ICSPost-bronchodilator FEV1/FVC below 0.7 (GOLD); below the lower limit of normal preferred in the 2013 Indian guideline
Bronchodilator reversibility (adults)FEV1 rise of more than 12% and more than 200 mLNot used to diagnose; absence of reversibility does not separate the two, and many COPD patients show significant reversibility
PEF variability (adults)Average daily diurnal variability above 10%Not a diagnostic criterion
Dominant inflammationEosinophilic (classic)Neutrophils, CD8+ T cells, macrophages
ExposureDefined by symptom and airflow variabilitySmoking; biomass fuel smoke in India
Treatment backboneICS-containing therapy; ICS-formoterol reliever in GINA Track 1LABA plus LAMA; ICS added by exacerbations and eosinophils
Long-acting bronchodilator without ICSNot appropriateFirst-line

Memory aid (our own framing, not a guideline phrase): COPD is persistent obstruction, so one fixed ratio confirms it. Asthma is variable obstruction, so you look for variability.

How COPD and Asthma Are Defined

GOLD defines COPD as a heterogeneous lung condition with chronic respiratory symptoms (breathlessness, cough, sputum, exacerbations). The symptoms arise from airway and/or alveolar abnormalities that cause persistent, often progressive airflow obstruction (GOLD 2023 executive summary).

GINA defines asthma as a heterogeneous disease with a history of respiratory symptoms that vary over time and in intensity, together with variable expiratory airflow limitation. Airway hyperresponsiveness and inflammation are common but not required for the diagnosis (GINA 2021 executive summary).

The definitions dictate the test. COPD needs proof that obstruction persists after a bronchodilator, while asthma needs proof that it varies. Because both present with chronic respiratory symptoms, read bedside signs carefully: finger clubbing, for instance, has its own differential, laid out in our clubbing causes post.

Spirometry in COPD vs Asthma

The COPD Criterion: Post-Bronchodilator FEV1/FVC Below 0.7

GOLD requires a post-bronchodilator FEV1/FVC below 0.7 to establish COPD (GOLD 2023 executive summary). The key word is post-bronchodilator: the ratio is measured after a bronchodilator has been given. A single ratio between 0.60 and 0.80 should be confirmed by repeat testing.

GOLD prefers the fixed 0.7 cut-off over the lower limit of normal (LLN) because it is simpler to apply, while acknowledging possible under-diagnosis in young adults and over-diagnosis in older people.

The joint Indian Chest Society and NCCP(I) guideline (2013) takes a different position. It prefers a post-bronchodilator ratio below the LLN (graded 1A) and allows the fixed 0.7 only where no valid reference equation exists. It states that the fixed 0.7 can misclassify over 20% of subjects compared with the LLN.

Grading COPD Severity by FEV1

GOLD grades spirometric severity from 1 to 4 and names the grades mild, moderate, severe and very severe. The word "mild" is reserved for spirometric severity. The FEV1 percent-predicted bands below are quoted from the 2013 Indian guideline, which reports the GOLD grading.

GOLD gradeNameFEV1 % predicted
1Mild≥80%
2Moderate50-79%
3Severe30-49%
4Very severeBelow 30%

These grades apply once the ratio has confirmed COPD. They are separate from the A, B and E groups used to choose treatment, covered below.

The Asthma Approach: Show Variability

Asthma has no single ratio threshold. GINA looks for a history of variable respiratory symptoms plus documented variable expiratory airflow limitation, and accepts several tests as evidence (GINA 2021 executive summary):

  • Significant bronchodilator reversibility
  • A positive bronchial provocation test
  • Excessive variability in peak expiratory flow (PEF)
  • Excessive variation in FEV1 between visits
  • A significant rise in FEV1 after a period of ICS treatment

More than one test is often needed, and GINA advises confirming the diagnosis before starting controller treatment if possible. A peak flow meter is a recommended but less reliable alternative to spirometry (Indian cross-sectional study, NPJ Prim Care Respir Med 2017).

Reversibility in COPD vs Asthma

In GINA's criteria, bronchodilator reversibility in adults means an FEV1 increase of more than 12% and more than 200 mL, with greater confidence above 15% and 400 mL (GINA 2022 primary care update). Because the rule joins the percentage and the volume, a small baseline FEV1 can show a rise above 12% that still falls short of 200 mL.

Test of variable airflowAdultsChildren
Bronchodilator reversibilityFEV1 rise of more than 12% and more than 200 mL (greater confidence above 15% and 400 mL)FEV1 rise of more than 12% of predicted
Average daily diurnal PEF variability (twice-daily readings over two weeks)Above 10%Above 13%

These thresholds are GINA's asthma criteria. Keep them separate from the COPD ratio of 0.7, which is a different test with a different purpose.

Why Reversibility Does Not Settle the Diagnosis

Reversibility is one of several accepted tests for asthma, yet a positive result does not exclude COPD. The Indian guideline states that absence of reversibility does not differentiate COPD from asthma (graded 1A) and that many COPD patients show significant reversibility (Indian Chest Society and NCCP(I) guideline).

GOLD takes the same line. Airflow obstruction that is not fully reversible is not specific for COPD, while full reversal after a bronchodilator argues against it (GOLD 2023 executive summary). So treat reversibility as one piece of evidence that adds to the history and the post-bronchodilator ratio, not as a verdict on its own.

Inflammation, Risk Factors and Patient Profile in COPD vs Asthma

Inflammation

Eosinophilic inflammation is classically associated with asthma and has been used to separate it from COPD. COPD inflammation is usually dominated by neutrophils, cytotoxic CD8+ T cells and alveolar macrophages (Tashkin and Wechsler, Int J COPD 2018).

The line is not clean. About one third of stable COPD patients show eosinophilic inflammation, and patients with features of both diseases vary: some show TH2-type inflammation with eosinophils and mast cells, others show more COPD-type symptoms with neutrophilic inflammation.

Risk Factors, Including India

Smoking is the key COPD risk factor, but only a minority of heavy smokers develop COPD. Biomass fuels such as wood, dung, crop residue and coal, burned in poor stoves, produce very high household air pollution, and non-smoking causes may account for up to 60-70% of COPD in low- and middle-income countries (GOLD 2023 executive summary). GOLD also notes that asthma and atopy in infancy are linked to later COPD.

The Indian guideline grades biomass smoke as a strong COPD risk factor (1A). It cites NFHS-3 for about 75% of Indian households using biomass fuel for cooking, and one study reporting airflow limitation in 8.1% of biomass-using households against 3.6% of LPG households (Indian Chest Society and NCCP(I) guideline).

A Lucknow tertiary-centre study of 416 COPD patients found 147 non-smokers (35.34%). Biomass smoke exposure was present in 67 of those 147 non-smokers (45.58%), against 18 of 269 smokers (6.69%) (Pandey et al., Lung India 2024). A non-smoker with persistent obstruction and a biomass history therefore still fits COPD.

One Indian Clinic Sample

In a cross-sectional Indian study of 115 patients with asthma and 33 with COPD, mean age was 47 years in the asthma group and 66 years in the COPD group. In the asthma group 91% were non-smokers, while every COPD patient was a current or ex-smoker. A symptom-free period of more than 2 weeks was the only symptom feature that still predicted asthma over COPD, with a sensitivity of 92% and specificity of 88% (NPJ Prim Care Respir Med 2017). This is one sample, not a general rule about age of onset, but it shows the idea: symptoms that come and go point towards asthma.

COPD Treatment: GOLD Groups A, B and E

GOLD 2023 assesses COPD with symptom scores and exacerbation history, and it merged the older groups C and D into a single group E (GOLD 2023 executive summary). Symptoms are scored with the modified Medical Research Council (mMRC) breathlessness scale or the COPD Assessment Test (CAT). The definitions and initial therapy below follow the GOLD 2023 review.

GroupExacerbations and symptomsInitial therapy
ANo exacerbation, or one not leading to admission; mMRC 0-1 or CAT below 10A bronchodilator
BSame exacerbation criterion; mMRC ≥2 or CAT ≥10Long-acting beta-agonist plus long-acting muscarinic antagonist (LABA+LAMA)
E≥2 exacerbations, or ≥1 leading to hospitalisationLABA+LAMA; consider LABA+LAMA+ICS if blood eosinophils are ≥300 cells/µL

For group B, GOLD now recommends dual LABA+LAMA over monotherapy. For group E, direct evidence for starting LABA+LAMA+ICS in treatment-naive patients is lacking, although it can be considered at an eosinophil count of 300 cells/µL or more.

The Role of Inhaled Corticosteroids in COPD

GOLD no longer encourages LABA+ICS in COPD. If an inhaled corticosteroid (ICS) is indicated, LABA+LAMA+ICS is preferred. The blood eosinophil count guides the decision: ICS has little or no effect below 100 cells/µL, benefit is more likely at 300 cells/µL or above, and 100 to 300 is a graded zone (GOLD 2023 executive summary). Several post-hoc analyses link eosinophil counts to ICS response, although the FLAME study found no such association (Tashkin and Wechsler).

The 2013 Indian guideline predates the ABE scheme. It states that LAMA is superior to LABA monotherapy (1A) and that ICS monotherapy should not be used (1A) (Indian Chest Society and NCCP(I) guideline). Read these as older national recommendations, not as current GOLD practice.

Asthma Treatment Ladder: GINA Tracks 1 and 2

GINA's stepwise approach for adults and adolescents offers two tracks. Track 1 is preferred and uses low-dose ICS-formoterol as the reliever at every step. Track 2 is the alternative when ICS-formoterol is unavailable or not preferred, and it uses a short-acting beta-agonist (SABA) reliever (GINA 2021 executive summary).

StepTrack 1 (ICS-formoterol reliever)Track 2 (SABA reliever)
1As-needed low-dose ICS-formoterol onlyICS taken whenever SABA is taken, preferable to SABA alone
2As-needed low-dose ICS-formoterol onlyRegular low-dose ICS plus as-needed SABA
3Maintenance-and-reliever therapy (MART), low-doseICS-LABA plus as-needed SABA
4MART with a medium maintenance doseICS-LABA plus as-needed SABA
5MART plus add-ons (LAMA, azithromycin, biologics for severe asthma)ICS-LABA plus add-ons

Step numbers follow the text of the GINA 2021 executive summary. Patients who have exacerbations despite ICS-LABA should receive at least medium-dose ICS-LABA before a LAMA is added (GINA 2022 primary care update).

The rationale for Track 1 is safety and adherence. As-needed ICS-formoterol cut severe exacerbations by 60% or more compared with SABA alone in mild asthma, and by almost two thirds in two large studies. SABA-only treatment is associated with an increased risk of asthma-related death, and adherence to daily ICS is poor when symptoms are mild or infrequent.

The sharpest contrast with COPD is the long-acting bronchodilator. It is first-line in COPD without ICS, yet GINA says a long-acting bronchodilator without ICS is not appropriate in asthma because of the exacerbation and death risk.

Asthma-COPD Overlap: When Both Are Present

GINA describes "asthma + COPD" as not a single disease entity. Until better discriminatory risk factors are identified, patients with diagnoses of both should receive ICS, and the COPD should otherwise be managed according to GOLD (GINA 2021 executive summary).

The two may co-exist, particularly in smokers and the elderly (GINA 2022 primary care update). GOLD 2023 takes a matching position: if COPD is accompanied by asthma, treat as asthma.

Common Mistakes When Comparing COPD and Asthma

Each pitfall below comes from applying one test or one drug class to the wrong disease:

  • Using reversibility as the deciding test. Absence of reversibility does not separate the two, and many COPD patients show significant reversibility.
  • Using a pre-bronchodilator ratio for COPD. GOLD requires a post-bronchodilator FEV1/FVC below 0.7, and a single ratio between 0.60 and 0.80 needs repeat testing.
  • Calling COPD "mild" from symptoms. In GOLD, "mild" describes spirometric severity only.
  • Choosing LABA+ICS for COPD. GOLD no longer encourages it; if an ICS is indicated, LABA+LAMA+ICS is preferred.
  • Giving a long-acting bronchodilator alone in asthma, or SABA alone in mild asthma. GINA does not consider the first appropriate, and SABA-only treatment is linked to a higher risk of asthma-related death.
  • Assuming COPD needs a smoking history. Biomass smoke is a strong risk factor in India.

If a stem gives you a post-bronchodilator ratio below 0.7 with persistent symptoms and a smoking or biomass history, think COPD and place the patient in a GOLD group. If it describes symptoms that come and go with large FEV1 or PEF swings, think asthma and go to the GINA steps. If it describes both, remember that GINA advises ICS for patients diagnosed with both conditions.

Putting COPD vs Asthma Together

COPD is persistent obstruction, confirmed by a post-bronchodilator FEV1/FVC below 0.7, graded by FEV1 and treated by GOLD group, with long-acting bronchodilators first and ICS only when exacerbations and eosinophils justify it. Asthma is variable obstruction, shown by reversibility, PEF variability or other variability tests, and treated on a GINA ladder in which ICS is central.

Because the two can overlap, no single test or feature, reversibility included, can decide a case alone. To test yourself, work through the respiratory medicine practice questions. This post stays with spirometry and treatment; for the imaging side of a breathless patient, see our pneumothorax X-ray post.

Practise this on Reflex

Turn what you just read into recall with 14 years of tagged PYQs.

FAQ

Frequently asked questions

The questions aspirants ask most about this topic.

GOLD requires a post-bronchodilator FEV1/FVC below 0.7 to establish COPD, and a single ratio between 0.60 and 0.80 should be confirmed by repeat testing. The 2013 Indian Chest Society and NCCP(I) guideline prefers a post-bronchodilator ratio below the lower limit of normal and allows the fixed 0.7 only where no valid reference equation exists.

GINA defines adult bronchodilator reversibility as an FEV1 increase of more than 12% and more than 200 mL, with greater confidence above 15% and 400 mL. In children the rule is an FEV1 rise of more than 12% of predicted. Average daily diurnal peak flow variability above 10% in adults and above 13% in children is another accepted test of variable airflow limitation.

No. The Indian Chest Society and NCCP(I) guideline states that absence of reversibility does not differentiate COPD from asthma and that many COPD patients show significant reversibility. GOLD adds that airflow obstruction that is not fully reversible is not specific for COPD, while full reversal after a bronchodilator argues against it.

Long-acting bronchodilators without an inhaled corticosteroid are first-line in COPD, for example LABA plus LAMA in GOLD groups B and E. GINA states they are not appropriate in asthma because of the risk of exacerbations and death. Asthma treatment is built around inhaled corticosteroid, with low-dose ICS-formoterol as the preferred reliever in GINA Track 1.

GINA describes asthma plus COPD as not a single disease entity. Until better discriminatory risk factors are identified, patients with diagnoses of both should receive an inhaled corticosteroid, and the COPD should otherwise be managed according to GOLD. GOLD 2023 similarly says that if COPD is accompanied by asthma, it should be treated as asthma.

Yes. Biomass smoke is graded as a strong COPD risk factor in the Indian guideline. In a Lucknow tertiary-centre study of 416 COPD patients, 147 (35.34%) were non-smokers, and 67 of those 147 (45.58%) had biomass smoke exposure.

Stay ahead in your preparation

Get expert tips, exam updates, and high-yield insights delivered straight to your inbox.

No spam. Unsubscribe anytime.

More in Medicine

View all →